Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 27, 2022
Reporting Period: Single event date (June 27, 2022)
Spero Therapeutics, Inc., a biopharmaceutical company, filed this report to disclose a significant regulatory event regarding its lead drug candidate, tebipenem HBr oral tablets, intended for the treatment of complicated urinary tract infections (cUTI).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for tebipenem HBr.
- Regulatory Status: The FDA determined the NDA could not be approved in its present form.
- Reason for Rejection: The FDA concluded that the Phase 3 cUTI study (ADAPT-PO) was insufficient to support approval.
- Requirement: Additional clinical study is required before approval can be considered.
Outlook, Management Commentary, and Risks
Management Commentary and Next Steps: The Company intends to promptly request a Type A meeting with the FDA to gain further insights into the pathway forward for potential regulatory approval of tebipenem HBr.
Risks and Contingencies: The primary risk identified is the delay in product commercialization due to the requirement for additional clinical studies. The outcome of the upcoming FDA meeting and the design of any required additional studies will determine the future regulatory timeline.
Key Facts for Investor Verification
- Verify the specific deficiencies cited in the FDA's Complete Response Letter regarding the ADAPT-PO study.
- Monitor the scheduling and outcomes of the requested Type A meeting with the FDA.
- Assess the potential timeline and cost implications of conducting additional clinical studies.
- Review the full text of the press release filed as Exhibit 99.1 for further details on the FDA's communication.